Monitoring Platelet Function During Continuous Hemodialysis

Changes in Platelet Function During Continuous Veno-venous Hemodialysis Using the Multiplate Device

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01837758

Enrollment

Registered

2013-04-23

Start date

2012-12-31

Completion date

2013-08-31

Last updated

2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platelet Function

Keywords

Platelet function, hemofiltration, Multiplate

Brief summary

Aim of the study is a description of changes in platelet function during continuous veno-venous hemodialysis or hemofiltration in patients on an intensive care unit using the Multiplate system.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Need for a continuous renal replacement therapy * Platelet Count \>100.000/nl

Exclusion criteria

* Pregnancy * Age \<18 years * Renal replacement therapy within the 7 days prior to enrollment

Design outcomes

Primary

Measure	Time frame	Description
ASPItest	Baseline, 6, 12, 24 and 48 hours	Area under the aggregation curve (AUC) after platelet stimulation with arachidonic acid at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.

Secondary

Measure	Time frame	Description
ADPtest	Baseline, 6, 12, 24 and 48 hours	Area under the aggregation curve (AUC) after platelet stimulation with adenosine diphosphate at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.
TRAPtest	Baseline, 6, 12, 24, 48 hours	Area under the aggregation curve (AUC) after platelet stimulation with thrombin-receptor-activating peptide 6 (TRAP-6) at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.
CT-INTEM	Baseline, 6, 12, 24 and 48 hours	Clotting time (CT) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in seconds at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration.
MCF-INTEM	Baseline, 6, 12, 24 and 48hours	Maximum clot firmness (MCF) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in millimeters at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration.

Other

Measure	Time frame	Description
Antiaggregatory Premedication	Baseline	Antiaggregatory medication taken prior to enrollment wil be recorded in the categories aspirin, clopidogrel, ticagrelor, cumarins and others.
Age	Baseline	Age of the patient at the point of enrollment
Anticoagulation for hemofiltration	Baseline	The anticoagulation used for hemofiltration will be recorded in the categories heparin and calcium citrate.
Dialysis filter	Basline	The brand of filter used for the hemofiltration or hemodialysis will be registered.
Height	Baseline	Height of the patient measured in centimeters.
Weight	Baseline	Weight of the patient measured in kilograms.
Gender	Baseline	—
ASA-Classification	Baseline	The ASA-Classification will be determined preoperatively.

Countries

Germany

Outcome results